We first assessed the cell cycle status of FTD-treated TP53-knockout cells in a TP53-knockout HCT116 cell line (hereafter referred to as p53-KO cells), which was previously generated using the CRISPR/Cas9 genome editing system [7, 21]. This evidence concerns the gene TP53 and frontotemporal dementia.